Indegene Limited has informed the Exchange about Transcript
INDGN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Indegene achieved major milestones in FY26 — Q4 revenues crossed ₹1,000 crores for the first time, and full-year revenues exceeded ₹3,500 crores (₹35,105 million), growing 23.6% in INR terms. Adjusted EBITDA for FY26 was ₹6,793 million (up 20.8%), though reported PAT declined 1.4% to ₹4,011 million due to a ₹203 million provision for a US class action settlement and ₹241 million FX impact. Excluding these one-offs, adjusted PAT was ₹4,583 million, up 12.7%. The company expanded its active customer base from 73 to 91, with $1 million+ customers growing from 41 to 53. Key wins include a GenAI-powered omnichannel deal with a top 5 customer (multi-product US portfolio over $1B) and a Tectonic engagement with the largest customer in Germany. Three acquisitions (BioPharm, Warn, Cake Communications) were completed. Revenue per employee rose to approximately $75,000. Cash position remains strong at ₹15,385 million, with a proposed dividend of ₹2.25 per share (up 12.5%).
Strong top-line growth and margin recovery expected in H2 FY27 as strategic investments in AI and talent yield returns. The company's AI-led solutions and expanding customer base beyond top 20 provide multiple growth levers. One-time legal provision creates near-term PAT pressure but removes overhang.